Episode Details
Back to EpisodesKidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
Published 3 years, 7 months ago
Description
Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future holds.